IXRS^®3 Decentralized Trials Support: Direct-To-Patient Supply Management

Direct-to-patient shipments are reshaping decentralized trials by placing patient convenience at the center of study design. Instead of traveling to every dispensing site visit, patients can receive investigational materials delivered directly to their homes, easing the time, cost, and stress associated with site visits. This approach not only improves retention but also helps patients stay on treatment without unnecessary disruptions.

Almac’s IXRS^®3 platform makes this possible with flexible configurations that adapt to each study’s protocol and local regulations. During drug assignment visits, sites can arrange home delivery according to patient preferences, including timing and location, while ensuring compliance with protocol requirements. If a replacement is needed—such as when supplies arrive damaged—new kits can be shipped directly to the patient, minimizing delays and preserving continuity of care.

Beyond convenience, IXRS^®3 safeguards patients by coordinating across depots, couriers, and, when necessary, home health providers, while protecting personal data under HIPAA and international privacy standards. This patient-centric model reduces the burden of participation, improves adherence, and makes clinical trials more accessible to diverse populations, ultimately advancing research while respecting the realities of patients’ lives.